WeChat· 生物药大时代·· 6 hours agoPickScore27
Pfizer Terminates Phase 2 Trial of CXCR5 Antibody PF-06835375
In brief
Pfizer has terminated a Phase 2 clinical trial of PF-06835375, an antibody targeting CXCR5. The Phase 2 study is no longer moving forward.
Why it matters
Two sources reported the same event
Source: WeChat · mp.weixin.qq.com